New web tool aims to keep men with Low-Risk prostate cancer on track without unnecessary treatment

NCT ID NCT05764005

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a web-based tool called MAP (Management of Active surveillance in Prostate Cancer) in 39 men aged 55+ with low-risk prostate cancer who were already on active surveillance. The tool provides education, helps coordinate care with primary care doctors, and offers self-management tips for cancer-related anxiety. The goal was to see if the tool is feasible and acceptable to patients and providers, with results to inform a larger future study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
web-based tool (MAP - Management of Active surveillance in Prostate Cancer)
What this could lead to
If successful, this could lead to a larger study that improves how men with low-risk prostate cancer are monitored, reducing unnecessary treatments.
What could go wrong
This is a small pilot study with only 39 participants, so results may not apply to everyone. The tool is behavioral, not a treatment, so it won't cure or control the cancer directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.